Research programme: antibacterials - Eisai Co Ltd/Global Antibiotic Research and Development Partnership/Takeda
Alternative Names: Antibiotics - Eisai Co Ltd/Global Antibiotic Research and Development Partnership/TakedaLatest Information Update: 28 Jan 2023
At a glance
- Originator Eisai Co Ltd; Global Antibiotic Research and Development Partnership; Takeda
- Developer Eisai Co Ltd; Global Antibiotic Research and Development Partnership; Institut Pasteur Korea; Takeda
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for research development in Bacterial-infections in Japan
- 28 Jan 2023 No recent reports of development identified for research development in Bacterial-infections in Switzerland
- 12 Dec 2018 The Global Antibiotic Research and Development Partnership, Eisai Co Ltd and Takeda enter into a multi-partner agreement to discover and develop antibacterials